|
|
|
Insider
Information: |
Krognes Steve E. |
Relationship: |
Director |
City: |
Burlingame |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
62,448 |
|
Indirect Shares
|
850,000 |
|
|
Direct
Value |
$1,099,211 |
|
|
Indirect Value
|
$17,527,000 |
|
|
Total
Shares |
912,448 |
|
|
Total
Value |
$18,626,211 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
14
|
Stock
price went up :
|
0
|
3
|
Stock
price went down : |
0
|
11
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
59.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Denali Therapeutics Inc. |
DNLI |
Director |
2024-05-31 |
53,308 |
2024-05-31 |
850,000 |
Premium* |
|
Guardant Health, Inc. |
GH |
Director |
2024-06-12 |
9,140 |
2023-06-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
42 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
GH |
Guardant Health, Inc. |
Director |
|
2024-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
154 |
3,393 |
0 |
- |
|
GH |
Guardant Health, Inc. |
Director |
|
2024-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
155 |
3,548 |
0 |
- |
|
GH |
Guardant Health, Inc. |
Director |
|
2024-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,592 |
9,140 |
0 |
- |
|
DNLI |
Denali Therapeutics Inc. |
CFO and Treasurer |
|
2020-03-30 |
4 |
S |
$19.48 |
$27,817 |
D/D |
(1,428) |
1,006,488 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
CFO and Treasurer |
|
2021-02-09 |
4 |
S |
$74.38 |
$108,135 |
D/D |
(1,448) |
12,979 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
CFO and Treasurer |
|
2021-02-11 |
4 |
S |
$70.17 |
$213,480 |
D/D |
(3,035) |
97,587 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
CFO and Treasurer |
|
2021-08-19 |
4 |
S |
$49.52 |
$113,263 |
D/D |
(2,285) |
95,302 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
CFO and Treasurer |
|
2022-01-05 |
4 |
S |
$44.75 |
$99,569 |
D/D |
(2,225) |
124,077 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
CFO and Treasurer |
|
2022-02-09 |
4 |
S |
$37.09 |
$48,073 |
D/D |
(1,296) |
122,781 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
CFO and Treasurer |
|
2022-02-11 |
4 |
S |
$34.69 |
$88,806 |
D/D |
(2,560) |
120,221 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2022-08-19 |
4 |
S |
$33.22 |
$74,845 |
D/D |
(2,253) |
149,468 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2023-01-05 |
4 |
S |
$28.44 |
$84,467 |
D/D |
(2,970) |
146,498 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2023-02-08 |
4 |
S |
$30.88 |
$42,522 |
D/D |
(1,377) |
145,121 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2023-02-13 |
4 |
S |
$30.10 |
$63,782 |
D/D |
(2,119) |
143,002 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2023-08-21 |
4 |
S |
$22.60 |
$32,069 |
D/D |
(1,419) |
145,799 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2024-01-05 |
4 |
S |
$19.43 |
$62,331 |
D/D |
(3,208) |
142,591 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2024-02-13 |
4 |
S |
$17.29 |
$47,548 |
D/D |
(2,750) |
139,841 |
0 |
% |
|
42 Records found
|
|
Page 2 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|